Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
Ian Landells, Colleen Marano, Ming-Chun Hsu, et al.
Journal of the American Academy of Dermatology (2015) Vol. 73, Iss. 4, pp. 594-603
Open Access | Times Cited: 209

Showing 1-25 of 209 citing articles:

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
April W. Armstrong, Charlotte Read
JAMA (2020) Vol. 323, Iss. 19, pp. 1945-1945
Closed Access | Times Cited: 1581
The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update
Patrick F. van Rheenen, Marina Aloi, Amit Assa, et al.
Journal of Crohn s and Colitis (2020) Vol. 15, Iss. 2, pp. 171-194
Open Access | Times Cited: 504
Psoriasis: Which therapy for which patient
Shivani B. Kaushik, Mark Lebwohl
Journal of the American Academy of Dermatology (2018) Vol. 80, Iss. 1, pp. 43-53
Open Access | Times Cited: 247
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)
Kevin Winthrop, Xavier Mariette, J.T. Silva, et al.
Clinical Microbiology and Infection (2018) Vol. 24, pp. S21-S40
Open Access | Times Cited: 224
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients
Alan Menter, Kelly M. Cordoro, Dawn Marie R. Davis, et al.
Journal of the American Academy of Dermatology (2019) Vol. 82, Iss. 1, pp. 161-201
Closed Access | Times Cited: 174
Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis
Paolo Gisondi, G. F. Altomare, Fabio Ayala, et al.
Journal of the European Academy of Dermatology and Venereology (2017) Vol. 31, Iss. 5, pp. 774-790
Open Access | Times Cited: 166
Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness
Ya‐Chu Tsai, Tsen‐Fang Tsai
Therapeutic Advances in Musculoskeletal Disease (2017) Vol. 9, Iss. 11, pp. 277-294
Open Access | Times Cited: 117
Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis
Caleb Jeon, Sahil Sekhon, Di Yan, et al.
Human Vaccines & Immunotherapeutics (2017) Vol. 13, Iss. 10, pp. 2247-2259
Open Access | Times Cited: 103
Efficacy and safety of ixekizumab in a phase III , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( IXORA ‐ PEDS )
Amy S. Paller, Marieke M.B. Seyger, Gabriel A. Magariños, et al.
British Journal of Dermatology (2020) Vol. 183, Iss. 2, pp. 231-241
Open Access | Times Cited: 91
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial
Seth Forman, David M. Pariser, Yves Poulin, et al.
Journal of Investigative Dermatology (2020) Vol. 140, Iss. 12, pp. 2359-2370.e5
Open Access | Times Cited: 89
Pediatric psoriasis: Evolving perspectives
Lawrence F. Eichenfield, Amy S. Paller, Wynnis L. Tom, et al.
Pediatric Dermatology (2018) Vol. 35, Iss. 2, pp. 170-181
Open Access | Times Cited: 87
Systemic Treatment of Pediatric Psoriasis: A Review
Maddalena Napolitano, Matteo Megna, Anna Balato, et al.
Dermatology and Therapy (2016) Vol. 6, Iss. 2, pp. 125-142
Open Access | Times Cited: 86
Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
Akshitha Thatiparthi, Amylee Martin, Jeffrey Liu, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 4, pp. 425-442
Open Access | Times Cited: 84
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients
Matteo Megna, Elisa Camela, Teresa Battista, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 1, pp. 25-41
Closed Access | Times Cited: 42
Treatment of non-systemic juvenile idiopathic arthritis
Susan Shenoi, Gerd Horneff, Amita Aggarwal, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 3, pp. 170-181
Closed Access | Times Cited: 9
Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors
Alireza Jafarzadeh, Elham Behrangi, Mina Khosravi, et al.
Inflammopharmacology (2025) Vol. 33, Iss. 4, pp. 1617-1672
Closed Access | Times Cited: 1
Safety of Systemic Agents for the Treatment of Pediatric Psoriasis
Inge M. G. J. Bronckers, Marieke M.B. Seyger, Dennis P. West, et al.
JAMA Dermatology (2017) Vol. 153, Iss. 11, pp. 1147-1147
Open Access | Times Cited: 87
Biologics for the primary care physician: Review and treatment of psoriasis
Eric D. Schadler, Bernhard Ortel, Stephanie Mehlis
Disease-a-Month (2018) Vol. 65, Iss. 3, pp. 51-90
Closed Access | Times Cited: 82
Treatment of severe psoriasis in children: recommendations of an Italian expert group
Anna Belloni Fortina, Federico Bardazzi, Samantha Berti, et al.
European Journal of Pediatrics (2017) Vol. 176, Iss. 10, pp. 1339-1354
Closed Access | Times Cited: 73
Safety of selective IL ‐23p19 inhibitors for the treatment of psoriasis
Jeffrey Crowley, Richard B. Warren, Jennifer Cather
Journal of the European Academy of Dermatology and Venereology (2019) Vol. 33, Iss. 9, pp. 1676-1684
Open Access | Times Cited: 72
Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis
Z.Z.N. Yiu, L.S. Exton, Zarif K. Jabbar‐Lopez, et al.
Journal of Investigative Dermatology (2016) Vol. 136, Iss. 8, pp. 1584-1591
Open Access | Times Cited: 70
Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?
Mina Amin, Daniel J. No, Alexander Egeberg, et al.
American Journal of Clinical Dermatology (2017) Vol. 19, Iss. 1, pp. 1-13
Closed Access | Times Cited: 70
Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study
Sandra Philipp, Alan Menter, Arjen Nikkels, et al.
British Journal of Dermatology (2020) Vol. 183, Iss. 4, pp. 664-672
Open Access | Times Cited: 67
Anti‐IL‐23 and Anti‐IL‐17 Biologic Agents for the Treatment of Immune‐Mediated Inflammatory Conditions
Jillian Frieder, Darío Kivelevitch, Isabel Haugh, et al.
Clinical Pharmacology & Therapeutics (2017) Vol. 103, Iss. 1, pp. 88-101
Closed Access | Times Cited: 65
Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease
David Mack, Eric I. Benchimol, Jeff Critch, et al.
Gastroenterology (2019) Vol. 157, Iss. 2, pp. 320-348
Open Access | Times Cited: 62
Page 1 - Next Page

Scroll to top